Intravitreal Fluocinolone Acetonide Implant (ILUVIEN) for the Treatment of Retinal Conditions. A Review of Clinical Studies.

Yusuf Mushtaq, Maryam M Mushtaq, Zisis Gatzioufas, Matteo Ripa, Lorenzo Motta, Georgios D Panos

Journal: Drug design, development and therapy 2023;17():961-975

PMID: 37020801

Abstract

Fluocinolone acetonide (FAc) intravitreal implant (Iluvien) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non-infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.

Address: Department of Ophthalmology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust & School of Medicine, University of Nottingham, Nottingham, UK.; Department of Acute Medicine, Luton and Dunstable University Hospitals NHS Trust, Luton, UK.; Department of Ophthalmology, Basel University Hospital & University of Basel School of Medicine, Basel, Switzerland.; Ophthalmology Unit, "Fondazione Policlinico Universitario A. Gemelli IRCCS", Rome, Italy.; Department of Ophthalmology, William Harvey Hospital, East Kent Hospitals University NHS Foundation Trust, Kent, UK.

DOI: 10.2147/DDDT.S403259

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/retinaldisorders.html

MeSH Terms: Humans, Diabetic Retinopathy, Drug Implants, Fluocinolone Acetonide, Glucocorticoids, Intravitreal Injections, Macular Edema, Retinal Diseases, Anti-Inflammatory Agents